Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.
CONCLUSIONS: In older patients with T2DM, canagliflozin showed small but significant reductions in total hip BMD and increases in bone formation and resorption biomarkers, due at least in part to weight loss.
PMID: 26580234 [PubMed - as supplied by publisher]
Source: Diabetes Metab - Category: Endocrinology Authors: Bilezikian JP, Watts NB, Usiskin K, Polidori D, Fung A, Sullivan D, Rosenthal N Tags: J Clin Endocrinol Metab Source Type: research
More News: Canagliflozin | CT Scan | DEXA Scan | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Diabetes Type 2 | Endocrinology | Estradiol | Invokana | Study | Weight Loss | Women
MedWorm Privacy Policy
Disclaimer
Copyright © MedWorm 2006-2024